Irene Kuter

TL;DR: Capecitabine is an active drug in the treatment of paclitaxel-refractory metastatic metastatic breast cancer and has a favorable toxicity profile with the added advantage of being an oral drug administered at home.

TL;DR: In this article, the authors investigated whether early alterations of myocardial strain and blood biomarkers predict incident cardiotoxicity in patients with breast cancer during treatment with anthracyclines, taxanes, and trastuzumab.

TL;DR: Cardiac troponin plasma concentrations and longitudinal strain predict the development of cardiotoxicity in patients treated with anthracyclines and trastuzumab, and the 2 parameters may be useful to detect chemotherapy-treated patients who may benefit from alternative therapies, potentially decreasing the incidence ofCardiotoxicity and its associated morbidity and mortality.

TL;DR: Single-agent atezolizumab was well tolerated and provided durable clinical benefit in patients with mTNBC with stable or responding disease and in earlier lines of treatment.

TL;DR: Early increases in TnI and MPO levels offer additive information about the risk of cardiotoxicity in patients undergoing doxorubicin and trastuzumab therapy, and independent validation is necessary before application to clinical practice.